BOUST: Bougie Sleeve Trial

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT02937649
Collaborator
(none)
1,658
12
2
50.4
138.2
2.7

Study Details

Study Description

Brief Summary

Staple-line leak is the most frequent and incapacitating complication after laparoscopic sleeve gastrectomy (LSG). The aim of this prospective randomized trial is to compare the staple-line leak rate after LSG according to the use of a standard bougie calibre (34, 36 or 38 Fr) or 48-Fr, assuming that a higher diameter is correlated with a lower risk of leak, without lowering long-term weight loss.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Laparoscopic sleeve gastrectomy using 48-Fr bougie
  • Procedure: Laparoscopic sleeve gastrectomy using standard care bougie
N/A

Detailed Description

Laparoscopic sleeve gastrectomy (LSG) has become an increasing bariatric procedure. The most common complication is gastric leak from the staple line, observed in approximately 3% of cases, and can result in long and incapacitating treatment. The diameter of the bougie used to calibrate the remnant stomach could impact the rate of gastric leak, a higher diameter being correlated with a lower risk of leak, without lowering long-term weight loss.

The aim of this prospective randomized trial is to compare the outcomes of LSG according to the use of a standard care bougie calibre or 48-Fr on postoperative gastric leak and mid-term weight loss.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1658 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Multicentric Randomized Prospective Study Assessing the Impact of the Bougie Calibration Size During Laparoscopic Sleeve Gastrectomy on the Rate of Postoperative Staple-line Leak Rate
Anticipated Study Start Date :
Sep 20, 2020
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Laparoscopic sleeve gastrectomy using 48-Fr bougie

Patients will undergo laparoscopic sleeve gastrectomy with a 48-Fr (16 mm) bougie

Procedure: Laparoscopic sleeve gastrectomy using 48-Fr bougie
After gastric mobilization, the 48-Fr bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.

Active Comparator: Laparoscopic sleeve gastrectomy using standard care bougie

Patients will undergo laparoscopic sleeve gastrectomy with a standard care bougie (34, 36 or 38-Fr)

Procedure: Laparoscopic sleeve gastrectomy using standard care bougie
After gastric mobilization, the standard care bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.

Outcome Measures

Primary Outcome Measures

  1. Postoperative gastric leak rate [30 days following the procedure]

    Postoperative gastric leak rate during the first month following the procedure will be proven either on: Morphologic examination (with contrast ingestion) Blue dye test during surgical reintervention or postoperative course Contrast opacification during endoscopy

Secondary Outcome Measures

  1. Postoperative morbidity rate [90 days following the procedure]

    Postoperative morbidity rate will be calculated regarding any complication occurring 90 days following the procedure.

  2. Short-term weight loss [At 3 and 6 months after the procedure]

    Short-term weight loss will be assessed by calculation of excess weight loss at 3 and 6 months after the procedure.

  3. Mid-term weight loss [At 1 and 2 years after the procedure]

    Mid-term weight loss will be assessed by calculation of excess weight loss at 1 and 2 years after the procedure.

  4. Quality of life related to health [At 3 months, 6 months, 1 year and 2 years after the procedure]

    Quality of life related to health will be assessed at 3 months, 6 months, 1 year and 2 years after the procedure with the validated GIQLI scale (Gastro Intestinal Quality of Life Index)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients between 18 and 70 years

  • Sleeve gastrectomy as a primary bariatric procedure

  • Body Mass Index (BMI) > 40 kg/m² or > 35 kg/m² associated with at least one comorbidity susceptible to improve after surgery (including arterial hypertension, obstructive sleep apnea syndrome and other severe respiratory disorders, severe metabolic disorders, particularly type 2 diabetes, incapacitating osteo-articular disorders, non alcoholic steatohepatitis)

  • Decision for intervention after multidisciplinary discussion

  • Written informed consent

Exclusion Criteria:
  • Previous upper abdominal surgery (cholecystectomy excepted)

  • ASA (American Society of Anesthesiologists) score > 3

  • Ongoing pregnancy or breast feeding

  • Esophagus pathology or disorder (esophageal varices, esophageal diverticula, esophageal tumors, esophageal strictures)

  • Coagulation disorder

  • Patient not covered by social security service and patient on AME

  • Patient under legal guardianship and trusteeship

  • Patient with known silicon allergy (calibration bougie contains medical silicon)

  • More generally, all other contraindications to the use of esophageal bougie MID-TUBE that have been the subject of a scientific paper or have been identified by the practitioner or practitioners

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hôpital Ambroise Paré Boulogne-Billancourt France 92104
2 Hôpital Côte de Nacre CHU de Caen Caen France 14033
3 CHU Antoine Béclère Clamart France 92140
4 Centre hospitalier Intercommunal de Créteil Créteil France 94010
5 Hôpital MICHALLON, CHU de Grenoble La Tronche France 38700
6 Hôpital Dupuytren - Limoges Limoges France 87042
7 Clinique de l'Yvette Longjumeau France 91120
8 Service de chirurgie générale et digestive, œsogastrique et bariatrique - Hôpital Bichat Paris France 75018
9 CHI - Centre Hospitalier Poissy/Saint-Germain-en-Laye Poissy France 78300
10 CH Saint-Denis Saint-Denis France 93200
11 Clinique Mutualiste Chirurgicale Saint-Étienne France 42100
12 Hôpitaux de Brabois Vandœuvre-lès-Nancy France 54500

Sponsors and Collaborators

  • Assistance Publique - Hôpitaux de Paris

Investigators

  • Principal Investigator: Hadrien TRANCHART, Dr, Assistance Publique - Hôpitaux de Paris

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT02937649
Other Study ID Numbers:
  • P150933
First Posted:
Oct 18, 2016
Last Update Posted:
Aug 18, 2020
Last Verified:
Nov 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Assistance Publique - Hôpitaux de Paris
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 18, 2020